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Antimicrobial hostdefensepeptidesconstitute amajor
component of innate immune systems. Expectations
are high to develop them into a novel class of anti-
infective agents. In this issue of Chemistry & Biology,
Hilpert et al. [1] describe new design and peptide
synthesis strategies for systematically investigating
such concepts.
Antimicrobial host defense peptides (HDPs) are na-
ture’s most abundant antibiotics [2]. Virtually every life
form produces an array of peptides which help to cre-
ate local barriers for competing microbes. Throughout
the evolution of higher organisms, microbes were pres-
ent and there was a vital need to control them; in
this scenario, HDPs apparently constitute a useful
instrumentarium that was worth conserving and devel-
oping [3]. Considering the current dilemma of ever-
increasing antibiotic resistance, which makes anti-
biotics rather short-lived drugs, it remains enigmatic
why, after millions of years of application, HDPs are still
effective [4].
HDPs are genetically encoded and derive from pre-
cursor peptides through proteolytic activation. Close to
1000 naturally occurring HDPs have been described to
date from bacteria, fungi, and plants to invertebrates,
amphibians, and mammals (http://www.bbcm.univ.
trieste.it/wtossi/amsdb.html). There is enormous struc-
tural diversity among HDPs, and the only conserved
features are (1) small size (10–50 amino acids), (2) an
overall positive charge, and (3) amphiphilic properties.
Various subgroups have been defined, such as peptides
containing disulphide bridges and b sheet or helical
segments (e.g., human a- and b-defensins, plectasin,
protegrins). These peptides have defined three-dimen-
sional structures in solution and may contain conserved
structural motifs [5]. Other classes of HDPs comprise
linear a-helical peptides (e.g., cecropins, magainins)
and extended peptides (e.g., indolicidin) rich in certain
amino acids such as glycine, arginine, proline, and
tryptophan [2, 6]. These groups of peptides are highly
flexible and they only adopt amphipathic features in
the presence of membranes and membrane-mimicking
solvents [2, 6].
HDPs Are Multifunctional Antibiotics
As indicated by the descriptive term ‘‘antimicrobial pep-
tides,’’ these agents have the widest possible spectrum
of activity. They kill gram-negative and gram-positive
bacteria as well as fungi and parasites, and they are
also able to antagonize viruses. Such a broad activity
excludes the existence of a defined molecular target,
and it is assumed that HDPs impair the integrity of
microbial membranes and cell envelopes (reviewed in
[2, 6, 7]). Indeed, the cationic, amphiphilic design ofHDPs, i.e., the clustering of charged and hydrophobic
side chains in defined surface areas of the molecules, ap-
pears to be optimal for such activities. The positive
charge ensures accumulation on microbial cell surfaces,
which contain acidic polymers such as lipopolysaccha-
ride (LPS) and wall teichoic acids (WTA); it also promotes
subsequent interaction with cytoplasmic membranes
that, unlike cellular membranes of higher organisms,
also have a negative surface charge. This feature pro-
vides some target cell specificity and is obviously
relevant for the activity of HDPs in vivo, since a major
counterstrategy of microbes to reduce their susceptibil-
ity to the peptides is based on the reduction of negative
charges in the cell envelope [4].
The impact of HDPs on the physical integrity of
membranes has been studied intensively on model
membranes, and various models exist to describe
such activities [2, 6, 7]. However, the actual killing of
microbes may require activities of HDPs beyond gross
membrane permeabilization. The amphiphilic cationic
design enables a maximum of interactions in biological
systems, and there are reports on direct effects of cat-
ionic peptides on bacterial respiratory chains [8], on
cell wall lytic enzymes [9], and on intracellular targets
(reviewed in [2, 6]), particularly for some flexible pep-
tides which may pass through the membrane without
causing much damage. HDP interference with viral
infections may also be mediated through interactions
with viral receptors [10, 11]. Full characterization of the
activities of these peptides beyond membrane disrup-
tion is an area in need of much more attention in future
research.
With HDPs, nature has apparently designed ‘‘dirty’’
drugs that simultaneously disturb various biological
functions with low potency rather than antibiotics which
effectively block one specific target [4]. Since HDPs
have been effective for billions of years, the question
may be asked, ‘‘Could such a concept provide anti-
biotics with a half-life of more than just a decade, and
therefore be considered for future antibiotic drug
development?’’
HDPs Modulate Innate Immunity
Cationic amphiphilic peptides not only have direct anti-
biotic effects, but there is increasing evidence that they
are also potent modulators of innate immunity [12]. A
whole range of immunostimulatory activities is currently
being investigated for various HDPs, including attrac-
tion of immune cells (classical chemokine activity), mod-
ulation of chemokine expression, induction of immune
cell differentiation, angiogenesis, and wound healing
[13]. The ability of HDPs to bind to microbial surface
molecules such as LPS and lipoteichoic acids (LTA),
mentioned above in context with the antibiotic activity,
adds yet another attractive feature. LPS and LTA
strongly upregulate proinflammatory host responses,
and the overstimulation of these immune responses fre-
quently leads to fatal septic shock. Thus, peptide bind-
ing to these microbial surface molecules interferes
with their signaling capacity in inflammation, which
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systemic infections.
HDPs and Drug Development
The prospect of combining all these activities, the direct
antibiotic effect, the immunostimulatory effects that im-
prove clearance of microbial loads, and the capacity to
neutralize potentially harmful microbial compounds,
makes HDPs most attractive for the development of a
truly novel anti-infective strategy [14, 15]. However, the
road from a promising natural compound to a pharmaco-
logically active anti-infective drug is long, and HDPs so
far have had only limited success. Generally, peptides
are not amenable to extensive chemical modification,
a feature that is considered important in drug develop-
ment. Also, chemical synthesis of peptides is compara-
tively expensive and the cost-of-goods problem needs
to be considered in the development of peptide-based
drugs.
In this regard, Hilpert et al. [1] report on a major tech-
nological improvement for the systematic investigation
of HDPs. The authors describe a new design strategy
for enhancing antibiotic activity which became feasible
through a new peptide synthesis technology. Spot syn-
thesis on cellulose supports [16] was combined with
subsequent liberation of the peptides and robot-assis-
ted testing for antibiotic activity in microtiter plates.
Figure 1. Flow Chart of the Optimization Strategy for Antimicrobial
Host Defense Peptides
The sequences of the starting peptide Bac2A and of one of the best-
optimized peptides are given using the one-letter code of amino
acids. The image shows the robot-assisted spot synthesis of pep-
tides and subsequent activity testing in microtiter plates by means
of a luciferase-expressing P. aeruginosa strain (inset); loss of light
production indicates antimicrobial activity. Image provided by
R.E.W. Hancock.This approach enabled the cost effective production of
large numbers of peptides with systematic sequence
variations.
The design strategy is based on a synthetic peptide,
Bac2A (Figure 1), a derivative of the naturally occurring
bovine host defense peptide bactenecin that was
identified in previous optimization work with conven-
tional methodology [17]. The new strategy, outlined in
Figure 1, included scrambling the sequence of the 12
amino acid peptide, in which peptide size, charge, and
hydrophobicity were kept constant. This process identi-
fied an essential, short hydrophobic stretch of amino
acids that needs to be placed between two positively
charged side chains, but may be located anywhere in
the sequence. Computational quantitative structure-
activity relationship (QSAR) analysis yielded further
activity predictions which were experimentally vali-
dated. Based on the structure of the best peptide ob-
tained at this stage, another round of optimization was
performed using a complete amino acid substitution
experiment. Overall, HDPs with a 5- to 10-fold increase
in potency, as compared to the Bac2A peptide, were
obtained. The minimal inhibitory concentration (MIC)
values in the low microgram per milliliter range of con-
centrations against a broad spectrum of pathogens,
including gram-positive, gram-negative bacteria, and
a fungal strain, are clinically meaningful and warrant
further studies.
In their paper, Hancock and coworkers [1] addressed
the direct antibiotic effect only. However, to make use of
the full anti-infective capacity of HDPs, it will be neces-
sary to develop and include further automated assays
in the optimization process to assess the induction of
chemokine synthesis, induction of immune cell differen-
tiation, and wound healing. Technologically, this should
be feasible and we may see some of the most exciting
concepts in HDP research being systematically ana-
lyzed in the near future.
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